Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes (Q36964626)

17 August 2017

1 reference

title

Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes (English)

1 reference

17 August 2017

1 reference

1 reference

Derek Le Roith

1

1 reference

17 August 2017

publication date

1 November 2007

1 reference

Diabetes - Metabolism: Research and Reviews

17 August 2017

published in

1 reference

17 August 2017

volume

23

1 reference

17 August 2017

issue

8

1 reference

17 August 2017

page(s)

593-599

1 reference

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

17 August 2017

cites work

1 reference

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

7 January 2021

1 reference

7 January 2021

Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.

1 reference

7 January 2021

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

1 reference

7 January 2021

Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor

1 reference

7 January 2021

Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency

1 reference

7 January 2021

Critical nodes in signalling pathways: insights into insulin action

1 reference

7 January 2021

Characterisation of receptors for IGF-I and insulin; evidence for hybrid insulin/IGF-I receptor in human coronary artery endothelial cells.

1 reference

7 January 2021

Insulin and IGF-I action on insulin receptors, IGF-I receptors, and hybrid insulin/IGF-I receptors in vascular smooth muscle cells

1 reference

7 January 2021

The Long Acting Human Insulin Analog HOE 901: Characteristics of Insulin Signalling in Comparison to Asp(B10) and Regular Insulin

1 reference

7 January 2021

Glucose transport in cultured human skeletal muscle cells. Regulation by insulin and glucose in nondiabetic and non-insulin-dependent diabetes mellitus subjects

1 reference

7 January 2021

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

1 reference

7 January 2021

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

1 reference

7 January 2021

Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells

1 reference

7 January 2021

Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells

1 reference

7 January 2021

Anti-atherogenic effect of insulin in vivo.

1 reference

7 January 2021

Insulin improves myocardial blood flow in patients with type 2 diabetes and coronary artery disease

1 reference

7 January 2021

Insulin Affects Vascular Smooth Muscle Cell Phenotype and Migration Via Distinct Signaling Pathways

1 reference

7 January 2021

Insulin suppresses plasma concentration of vascular endothelial growth factor and matrix metalloproteinase-9.

1 reference

7 January 2021

Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice.

1 reference

7 January 2021

Insulin like growth factor-1 and insulin-like growth factor binding proteins: their possible roles in both maintaining normal retinal vascular function and in promoting retinal pathology

1 reference

7 January 2021

Treatment with insulin glargine does not suppress serum IGF-1

1 reference

7 January 2021

No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.776

1 reference

17 August 2017

1 reference